American Journal of Obstetrics & Gynecology
Volume 194, Issue 4 , Pages 961-966 , April 2006

Selective serotonin reuptake inhibitors and adverse pregnancy outcomes

  • Shi Wu Wen, MB, PhD

      Affiliations

    • OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine
    • Ottawa Health Research Institute, Clinical Epidemiology Program
    • Department of Epidemiology and Community Medicine, University of Ottawa Faculty of Medicine
    • Corresponding Author InformationReprint requests: Shi Wu Wen, MB, PhD, OMNI Research Group, Department of Obstetrics & Gynecology, University of Ottawa, Faculty of Medicine, 501 Smyth Rd, Box 241, Ottawa, Ontario, Canada, K1H 8L6.
    • ,
  • Qiuying Yang, MD, PhD

      Affiliations

    • OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine
    • Ottawa Health Research Institute, Clinical Epidemiology Program
    • McLauhlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Peter Garner, MD

      Affiliations

    • Deceased.
    • ,
  • William Fraser, MD, MSc

      Affiliations

    • Department of Obstetrics and Gynecology, University of Montreal Faculty of Medicine, Montreal, Quebec, Canada
    • ,
  • Olufemi Olatunbosun, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Saskatchewan Faculty of Medicine, Saskatoon, Saskatchewan, Canada
    • ,
  • Carl Nimrod, MD

      Affiliations

    • OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine
    • Ottawa Health Research Institute, Clinical Epidemiology Program
    • ,
  • Mark Walker, MSc, MD

      Affiliations

    • OMNI Research Group, Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine
    • Ottawa Health Research Institute, Clinical Epidemiology Program

Received 2 December 2005 ,Revised 16 January 2006 ,Accepted 12 February 2006.

References 

  1. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984;93:158–171
  2. Barron WM, Lindheimer MD. Preface and guidelines for prescribing drugs to pregnant women. In:  Barron WM,  Lindheimer MD editor. Medical disorders during pregnancy. St. Louis (MO): Mosby-Year Book; 1991;p. IX–XII
  3. Burbui C, Guaiana G, Hotopf M. Amitriptyline for in patients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry. 2004;37:93–97
  4. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396–412
  5. Hardman J, Limbird L. Goodman and Gilman's: the pharmacological basis of therapeutics. 9th ed.. New York: McGraw Hill; 1996;p. 445-6
  6. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?. CMAJ. 2005;172:1457–1459
  7. Chambers CD, Johnson KA, Dick LN, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015
  8. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288–291
  9. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:451–453
  10. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368–375
  11. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402–408
  12. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatr. 2003;60:720–726
  13. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spirey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multi-center study. JAMA. 1998;279:609–610
  14. Nulman I, Rovert J, Stewart D, Wolpin J, Gradner HA, Theis JG, et al. for the Motherisk Program, Hospital for Sick Children and University of Toronto Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258–262
  15. Pastuszak A, Schick-Boschetto B, Zuber C. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246–2248
  16. Hendrick V, Smith L, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188:812–815
  17. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol. 2005;25:59–73
  18. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. In:  Strom BL editors. Pharmacoepidemiology. 3rd ed.. Chichester, UK: Wiley; 2000;p. 325–345
  19. Commission on Professional and Hospital Activities . International classification of disease, 9th revision: clinical modification. Ann Arbor (MI): The Commission; 1992;
  20. Canadian classification of diagnostic, therapeutic, and surgical procedures. Ottawa, Ontario. Canada: Statistics Canada; 1986;
  21. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed.. Philadelphia: Lippincott Raven; 1998;
  22. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol. 2000;53:823–831
  23. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies: pilot-study, pharmacist and mother as sources for drug exposure data during pregnancy. Teratology. 1999;60:33–36
  24. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25:595–604
  25. Wogelius P, Norgaard M, Mutt Munk E. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiology and Drug Safety. 2005;14:S143
  26. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005;73:123–130
  27. Bjoro K, Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries: I, vasoactive effects of serotonin, PGF2α and PGE2. Acta Obstet Gynecol Scand. 1986;65:351–355
  28. Haugen G. The vasoactive effects of serotonin in normal and single umbilical artery cords in normotensive and hypertensive pregnancies. Hypertens Pregnancy. 1996;15:39–50

 Supported by a grant from The Hospital for Sick Kids Foundation (grant #XG-02-098) and by a research and development Research Allowance from The Canadian Institutes for Health Research (S.W.W.).Based in part on nonidentifiable data provided by the Saskatchewan Department of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health.Presented at the 26th Annual Meeting of the Society for Maternal Fetal Medicine, January 30 - February 4, 2006, Miami, FL.

PII: S0002-9378(06)00225-0

doi: 10.1016/j.ajog.2006.02.019

American Journal of Obstetrics & Gynecology
Volume 194, Issue 4 , Pages 961-966 , April 2006

Article Tools